

Renal Expression of Vascular Endothelial Growth Factor in Lupus Nephritis

Thesis

*Submitted for Partial Fulfillment of Masters Degree in
Pediatrics*

BY

Marwa Salah Abbass

M.B. B. CH. (2003)

Faculty of Medicine-Ain Shams University

Under the Supervision of

Prof. Yehia Mohammad El-Gamal

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Assis. Prof. Shereen Saad El-Sayed

Assistant Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Assis. Prof. Naglaa Samir Ahmed

Assistant Professor of Pathology

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2013

تحديد مستوي معامل النمو للخلايا المبطنه
للأوعية الدموية بالكلي عند الأطفال
المصابين بمرض الذئبة الحمراء

رسالة

توطئة للحصول علي درجة الماجستير في
طب الأطفال
مقدمة من

الطبيبة / مروة صلاح عباس
بكالوريوس الطب والجراحة
جامعة عين شمس (2003)

تحت إشراف

أ.د/ يحيي محمد الجمل

أستاذ طب الأطفال
كلية الطب - جامعة عين شمس

د / شيرين سعد السيد

أستاذ مساعد طب الأطفال
كلية الطب - جامعة عين شمس

د / نجلاء سمير أحمد

أستاذ مساعد قسم الباثولوجي
كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

2013



Acknowledgement

First of all great thanks to **"Allah"** who gave me the power to complete this work. Without His care nothing could be achieved.

I would like to express my endless gratitude to **Prof. Yehia Mohammad El Gamal**, Professor of Pediatrics, Faculty of Medicine - Ain Shams University, for his valuable supervision and support all through the whole work and for dedicating much of his precious time to accomplish this work.

My special thanks to **Assis. Prof. Shereen Saad El Sayed**, Assistant Professor of Pediatrics, Faculty of Medicine - Ain Shams University for her meticulous supervision and support throughout this work. I would like to express my great thanks to **Assis. Prof. Naglaa Samir Ahmed**, Assistant Professor of Pathology, Faculty of Medicine - Ain Shams University, for her efforts in the laboratory part of this work.

I would like to express my endless gratitude to my dear patients and their parents without her help and co-operation this work would have never been accomplished. May Allah grant them good health.

Last but not least, sincere gratitude to **My Family** for their continuous encouragement and spiritual support.

Marwa Salah Abbass



سورة البقرة الآية: ٣٢

Contents

Subjects	Page
• List of abbreviations.....	I
• List of tables	III
• List of figures.....	V
• Introduction	1
• Aim of the work.....	3
• Review of literature	
oLupus Nephritis	4
oNovel Tissue Biomarkers in Lupus Nephritis.....	32
oRenal expression of Vascular endothelial growth factor (VEGF) in Lupus Nephritis.....	38
• Patients and Methods	48
• Results	63
• Discussion & Conclusion	83
• Recommendations.....	93
• Summary.....	94
• References.....	99
• Appendix	i-iv
• Arabic summary	

List of Abbreviations

ACR	: American college of Rheumatology
ADPKD	: Autosomal dominant polycystic kidney disease
ANAs	: Antinuclear antibodies
Anti- dsDNA	: Antidouble Stranded deoxyribonucleic acid
BILAG	: British Isles Lupus Assessment Group
BLYS	: B lymphocyte stimulator
BUN	: Blood urea nitrogen
C	: Complement
CBC	: Complete blood count
CRP	: C-reactive protein
DPLN	: Diffuse proliferative lupus nephritis
ESR	: Erythrocyte sedimentation rate
ESRD	: End stage renal disease
GBM	: Glomerular basement membrane
GFR	: Glomerular filtration rate
GN	: Glomerulonephritis
Ig	: Immunoglobulin
IL	: Interleukin
INF-γ	: Interferon gamma
ISN/RPS	: International Society of Nephrology/ Renal Pathology Society
LN	: Lupus Nephritis

MCP-1	: Monocyte chemo-attractant protein-1
mEPCR	: Membrane expression of endothelial protein C receptor
MMF	: Mycophenolate mofetil
NGAL	: Nentrophil gelatinase associated lipocalin
NP	: Neuro-psychiatric
PAF	: Platelet activating factor
PDGF	: Platelet derived growth factor
PTCs	: Peritubular Capillaries
PTECs	: Proximal tubular epithelial cells
RBCs	: Red Blood cells
SD	: Standard Deviation
sF1T 1	: Soluble form of VEGF receptor-1
SLE	: Systemic lupus erythematosus
SLEDAI	: Systemic Lupus Erythmatosus Disease activity Index
SLICC/ACR	: Systemic Lupus International Collaborating Clincs/American College of Rheumatology
STAT-1	: Signal transducer and activator of transcription-1
sTM	Serum thrombomodulin
TNF-α	: Tumor necrosis factor-alpha
VEGF	: Vascular endothelial growth factor
VEGFRs	: Vascular endothelial growth factor receptors
WBCs	: White blood cells
WHO	: World Health Organization

List of Tables

Tables No.	Title	Page No.
Table (1)	International Society of Nephrology/ Renal Pathology Society (ISN/RPS- 2003) Classification of Lupus Nephritis	17
Table (2)	General guidelines for immunosuppressive therapy in lupus nephritis.	19
Table (3)	Relative doses and equivalent potencies of glucocorticoids.	50
Table (4)	Systemic Lupus Erythmatosus Disease activity Index (SLEDAI)	52
Table (5)	British Isles Lupus Assessment Group (BILAG) Index (Renal)	53
Table (6)	Systemic Lupus International Collaborating Clincs/American College of Rheumatology (SLICC/ACR) Damage Index.	57
Table (7)	Demographic and laboratory data of the studied patients with respect to VEGF expression; patients with mild expression and patients with mod/ strong expression.	65
Table (8)	Variation of the age at onset of SLE and gender of the studied patients in relation to VEGF expression.	70

Tables No.	Title	Page No.
Table (9)	Variation of the studied immunological markers in relation to VEGF expression in the first visit.	71
Table (10)	Variation of the studied immunological markers in relation to in VEGF expression in the last visit.	72
Table (11)	Effect of VEGF expression on renal functions in the studied patients in the first visit.	73
Table (12)	Effect of VEGF expression on renal functions in the studied patients in the last visit.	74
Table (13)	The effect of VEGF expression on SLEDAI and BILAG renal scores of the studied patients in the first visit.	75
Table (14)	The effect of VEGF expression on SLEDAI and BILAG renal scores of the studied patients in the Last visit.	76
Table (15)	The effect of VEGF expression on therapeutic modalities.	77
Table (16)	The effect of VEGF expression on activity index and chronicity index.	78
Table (17)	Correlations between renal expression of VEGF and some selected patients' data.	79

List of Figures

Figure No.	Title	Page No.
Fig. (1)	Schematic representation of a model for pathogenesis of renal disease in SLE suggesting the contribution of T and B cell infiltration in the progression of renal failure	10
Fig. (2)	Increased circulating VEGF decreases renal VEGF in lupus nephritis	42
Fig. (3)	Comparison between the studied patients and control group as regards the frequency of VEGF expression.	67
Fig. (4)	Distribution of our SLE patients as regards WHO classes of LN.	68
Fig. (5)	Variations of VEGF expression with the histological classes of LN.	69
Fig. (6)	Strong VEGF expression in glomerulus and tubular epithelial cells in the control group.	80
Fig. (7)	Class II LN with mild VEGF expression in tubular epithelial cells.	80
Fig.(8)	Class II LN with Moderate VEGF expression.	81
Fig. (9)	Class III LN with Moderate VEGF expression.	81
Fig. (10)	Class IV LN with mild VEGF expression.	82

Introduction

Systemic lupus erythromatosus is an autoimmune disease characterized by acute and chronic inflammation of various tissues of the body. The antibodies and accompanying cells of inflammation can affect tissues anywhere in the body. Lupus has the potential to affect a variety of areas. SLE most often harms the skin, heart, lungs, kidneys, joints and /or nervous system. The course of the disease is unpredictable with periods of illness (called flares) alternating with remission (*Anisur et al., 2008*).

The precise reason for the abnormal autoimmunity that causes lupus is not known (inherited genes, viruses, ultraviolet light, and certain medications) may all play some role (*D’Cruz et al., 2007*). Kidney disease is one of the commonest and the most serious manifestation of (SLE). Despite improvement in the medical care of SLE in the past two decades the prognosis of lupus nephritis remains unsatisfactory. Up to 25% of patients still develop end stage renal failure 10 years after onset of renal disease (*Mok, 2006*).

Renal biopsy is the gold standard for providing information on the histological classes of lupus nephritis and the relative degree of activity and chronicity in the glomeruli (*Mok, 2006*).

There is different tissue markers that has been associated with histological classes or renal functions deterioration in lupus nephritis. Intrarenal vascular endothelial growth factor mRNA expression predicts the deterioration of renal functions (VEGF expression) (*Avihingsanon et al., 2009*). Vascular endothelial growth factor (VEGF) has been shown to stabilize kidney functions in animal model of thrombotic microangiopathy (*Kim et al., 2000*).

The protective actions were principally mediated through preserved glomerular and peritubular capillary structures. This may help to preserve glomerular filtration rate by maintaining glomerular capillary filtration surface area as well as preventing tubulointerstitial fibrosis (*Kang and Johnson, 2003*). Hence patients with proliferative LN who had decreased intrarenal VEGF expression are at risk for a rapid decline of renal functions at the time of renal flare. The combination of renal pathology such as class III/ IV LN and reduced VEGF expression could predict poor renal survival (*Shulman et al., 1996*). VEGF plays a crucial role in the preservation of renal functions and may also serve as a useful biomarker in monitoring the progression of lupus nephritis (*Lemos et al., 2003*).

Aim of the Work

The aim of the present study is to try to correlate VEGF expression in the kidney with renal histopathology and prognosis of lupus nephritis.

Lupus Nephritis

Systemic lupus erythromatosus

Childhood systemic lupus erythromatosus generally presents between the ages of 3 and 15 years, with girls outnumbering boys 4: 1. SLE most often harms the skin, heart, lungs, kidneys, joints and/or nervous system. The clinical presentation of SLE is a function of its immunopathology (*Frieri et al., 2012*).

As many as 30% of sufferers have some dermatological symptoms (and 65% suffer such symptoms at some point), with 30% to 50% suffering from the classic malar rash (or butterfly rash) associated with the disease. Some may exhibit thick, red scaly patches on the skin (referred to as discoid lupus). Alopecia; mouth, nasal, and vaginal ulcers; and lesions on the skin are also possible manifestations (*James et al., 2005*).

The most commonly sought medical attention is for joint pain, with the small joints of the hand and wrist usually affected, although all joints are at risk. The Lupus Foundation of America estimates more than 90 percent of those affected will experience joint and/or muscle pain at some time during the course of their illness (*Hemminki et al., 2009*).